Regional experience of severe bronchial asthma therapy with the use of the "Benralizumab" drug in the Republic of Buryatia

The article demonstrates a modern method of pharmacotherapy for severe eosinophilic bronchial asthma using the genetically engineered immunobiological drug " benralizumab " (Fasenra) The effectiveness and safety of biological therapy in 13 patients (average age 61.37 + 2.42 years) with severe eosinophilic phenotype of bronchial asthma in the Republic of Buryatia were demonstrated based on the evaluation of clinical and functional indicators: severity and frequency of symptoms with assessment of asthma control using validated questionnaires AST and ACQ-5; frequency of exacerbations, need forsystemic glucocorticosteroids. The functional indicators - peak expiratory flow rate according to spirometry data; peripheral blood eosinophilia dynamics. The improvements of the condition of patients with severe bronchial asthma, including reduction in symptom frequency, achievement of controlled disease course (reduction in ACQ-5 score from 1.92+ 0.23 to 0.73 and increase in AST score from 15.83 + 2.3 to 22.3), absence of exacerbations during a one-year observation period, improvement in respiratory function indicators such as increased peak expiratory flow rate from 57.1 + 4.47% to 83.16 + 3.74% of predicted values, discontinuation of systemic glucocorticosteroids, significant reduction in the number of peripheral blood eosinophils to 0 in 98.5% of cases have been confirmed in real clinical practice with the use of the genetically engineered immunobiological drug "benralizumab" (Fasenra).